Delcath SystemsDCTH -3.77%72 Receivables Turnover is 1.93 as of Mar. 2026. GuruFocus rates DCTH with a GF Score™ of 72/100 and a GF Value™ of $37.21 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Delcath Systems ranks better than 62.73% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Delcath Systems's Revenue for the
three
months ended in Mar. 2026 was $24.99 Mil. Delcath Systems's average Accounts Receivable for the
three
months ended in Mar. 2026 was $12.95 Mil.
Hence, Delcath Systems's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.93.
Delcath Systems (NAS:DCTH) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Delcath Systems Receivables Turnover Related Terms
Delcath Systems Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Delcath Systems's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DCTH vs VMD, VREX, SI: Receivables Turnover Comparison
For the Medical Devices subindustry, Delcath Systems's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Delcath Systems Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Delcath Systems's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Delcath Systems (DCTH) has a Receivables Turnover of 1.93 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Delcath Systems and its competitors. According to the industry distribution chart, Delcath Systems ranks #303 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 37.3%.
Is Delcath Systems' Receivables Turnover too high?
Delcath Systems' current Receivables Turnover is 1.93. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Delcath Systems' value of 1.93 is 65% below this industry median. Based on the distribution chart, Delcath Systems ranks #303 out of 813 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Delcath Systems has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Delcath Systems' Receivables Turnover compare to VMD and VREX?
According to the Medical Devices & Instruments industry distribution chart, Delcath Systems ranks #303 out of 813 companies for Receivables Turnover. This puts Delcath Systems in the upper half of its industry. The industry median Receivables Turnover is 5.51. Delcath Systems' value of 1.93 is 65% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Delcath Systems's current Receivables Turnover of 1.93 is 65% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Delcath Systems and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Delcath Systems's current Receivables Turnover is 1.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delcath Systems stock overvalued right now?
Based on GuruFocus' analysis, Delcath Systems (DCTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $37.21, compared to a current price of $13.02 — trading 65% below its estimated fair value. The current Receivables Turnover is 1.93 and 65% below the Medical Devices & Instruments industry median of 5.51. Delcath Systems' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Delcath Systems (DCTH), the current Receivables Turnover is 1.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Delcath Systems (DCTH) Overvalued in 2026?
Based on GuruFocus' analysis, Delcath Systems stock appears to be undervalued.
The current stock price of $13.02 is trading 65% below its estimated GF Value™ of $37.21.
GuruFocus considers Delcath Systems to be Significantly Undervalued.
Key valuation signals for DCTH:
Receivables Turnover: 1.93
GF Value™: $37.21 vs. price of $13.02 (65% below fair value)
Industry Position: 65% below the Medical Devices & Instruments median (#303 of 813)
No single metric tells the full story. See the DCTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
72GF Score
Get the complete analysis for DCTH
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DCTH has been successfully added to your 
